EQS-News: BioCorRx Inc

/ Key word(s): Financial

BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales 14.08.2025 / 20:30 CET/CEST

The issuer is solely responsible for the content of…Read More

You might also be interested in reading Netskope extends gains following last week’s IPO.